• +1-646-491-9876
    • +91-20-67278686

    Search

    Diabetic Foot Ulcers-Pipeline Review H1 2017

    Diabetic Foot Ulcers-Pipeline Review H1 2017

    • Report Code ID: RW0001834325
    • Category Pharmaceuticals
    • No. of Pages 132
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Diabetic Foot Ulcers - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Foot Ulcers - Pipeline Review, H1 2017, provides an overview of the Diabetic Foot Ulcers (Metabolic Disorders) pipeline landscape.

    Diabetic foot ulcers are sores that occur on the feet of people with Type 1 Diabetes and Type 2 Diabetes. Symptoms include sores, ulcers, or blisters on the foot or lower leg, pain, walking with difficulty, discoloration in feet: black, blue, or red, cold feet and fever, skin redness or swelling, or other signs of infection. The predisposing factors include diabetic neuropathy, peripheral vascular disease, a foot deformity and history of tobacco use disorder.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Diabetic Foot Ulcers - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Foot Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 12, 6, 22, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

    Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Foot Ulcers (Metabolic Disorders) .
    - The pipeline guide reviews pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Diabetic Foot Ulcers (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Diabetic Foot Ulcers (Metabolic Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Diabetic Foot Ulcers (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 5
    List of Figures 6
    Introduction 7
    Publisher Report Coverage 7
    Diabetic Foot Ulcers - Overview 8
    Diabetic Foot Ulcers - Therapeutics Development 9
    Pipeline Overview 9
    Pipeline by Companies 10
    Pipeline by Universities/Institutes 14
    Products under Development by Companies 15
    Products under Development by Universities/Institutes 18
    Diabetic Foot Ulcers - Therapeutics Assessment 19
    Assessment by Target 19
    Assessment by Mechanism of Action 21
    Assessment by Route of Administration 23
    Assessment by Molecule Type 25
    Diabetic Foot Ulcers - Companies Involved in Therapeutics Development 27
    ANP Technologies Inc 27
    Anterogen Co Ltd 27
    Boston Therapeutics Inc 28
    CardioVascular BioTherapeutics Inc 28
    Celgene Corp 29
    Chrysalis BioTherapeutics Inc 29
    CytoTools AG 30
    EyeGene Inc 30
    FirstString Research Inc 31
    Genentech Inc 31
    GlaxoSmithKline Plc 32
    Human Stem Cells Institute 32
    Izun Pharmaceuticals Corp 33
    Lakewood-Amedex Inc 33
    MediWound Ltd 34
    NovaLead Pharma Pvt Ltd 34
    Oneness Biotech Co Ltd 35
    Osiris Therapeutics Inc 35
    Pherecydes Pharma SA 36
    RMB-Research GmbH 36
    Serodus ASA 37
    Stempeutics Research Pvt Ltd 37
    Stratatech Corp 38
    TechnoPhage SA 38
    Theravasc Inc 39
    Topadur Pharma AG 39
    USV Pvt Ltd 40
    viDA Therapeutics Inc 40
    ViroMed Co Ltd 41
    Diabetic Foot Ulcers - Drug Profiles 42
    3K3A-APC - Drug Profile 42
    ALLO-ASC - Drug Profile 44
    ANP-017 - Drug Profile 46
    AP-185 - Drug Profile 47
    APO-2 - Drug Profile 48
    AUP-16 - Drug Profile 49
    becaplermin biosimilar - Drug Profile 50
    Cell Therapy to Activate Cathelicidin for Diabetic Foot Ulcers and Crural Ulcer - Drug Profile 51
    Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers - Drug Profile 53
    CODA-001 - Drug Profile 54
    CVBT-141B - Drug Profile 56
    Cyndacel-M - Drug Profile 58
    daprodustat - Drug Profile 60
    diperoxochloric acid - Drug Profile 63
    EG-Decorin - Drug Profile 67
    epidermal growth factor biosimilar - Drug Profile 68
    EscharEx - Drug Profile 69
    esmolol hydrochloride - Drug Profile 72
    Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers - Drug Profile 73
    Granexin - Drug Profile 74
    Heberprot-P - Drug Profile 76
    IMSP-001 - Drug Profile 77
    Ipoxyn - Drug Profile 78
    IZN-6D4 - Drug Profile 79
    MT-003 - Drug Profile 80
    NAS-911 - Drug Profile 81
    Neovasculgen - Drug Profile 83
    Nu-2 - Drug Profile 84
    Nu-3 - Drug Profile 85
    ON-101 - Drug Profile 87
    OTI-1501 - Drug Profile 89
    PDA-002 - Drug Profile 90
    PP-2351 - Drug Profile 91
    Recombinant Protein for Wounds, Bone Regeneration and Diabetic Ulcers - Drug Profile 92
    RG-7880 - Drug Profile 93
    rusalatide acetate - Drug Profile 94
    SER-190 - Drug Profile 98
    sodium nitrite SR - Drug Profile 99
    Statmicoll - Drug Profile 101
    Stempeucel - Drug Profile 102
    TOPN-53 - Drug Profile 105
    TP-102 - Drug Profile 106
    V-10 - Drug Profile 107
    V-2248 - Drug Profile 108
    VM-202 - Drug Profile 109
    VTI-1000 Series - Drug Profile 113
    VTI-3000 Series - Drug Profile 114
    Diabetic Foot Ulcers - Dormant Projects 115
    Diabetic Foot Ulcers - Discontinued Products 118
    Diabetic Foot Ulcers - Product Development Milestones 119
    Featured News & Press Releases 119
    Appendix 128
    Methodology 128
    Coverage 128
    Secondary Research 128
    Primary Research 128
    Expert Panel Validation 128
    Contact Us 128
    Disclaimer 129

    List of Tables

    Number of Products under Development for Diabetic Foot Ulcers, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Diabetic Foot Ulcers - Pipeline by ANP Technologies Inc, H1 2017
    Diabetic Foot Ulcers - Pipeline by Anterogen Co Ltd, H1 2017
    Diabetic Foot Ulcers - Pipeline by Boston Therapeutics Inc, H1 2017
    Diabetic Foot Ulcers - Pipeline by CardioVascular BioTherapeutics Inc, H1 2017
    Diabetic Foot Ulcers - Pipeline by Celgene Corp, H1 2017
    Diabetic Foot Ulcers - Pipeline by Chrysalis BioTherapeutics Inc, H1 2017
    Diabetic Foot Ulcers - Pipeline by CytoTools AG, H1 2017
    Diabetic Foot Ulcers - Pipeline by EyeGene Inc, H1 2017
    Diabetic Foot Ulcers - Pipeline by FirstString Research Inc, H1 2017
    Diabetic Foot Ulcers - Pipeline by Genentech Inc, H1 2017
    Diabetic Foot Ulcers - Pipeline by GlaxoSmithKline Plc, H1 2017
    Diabetic Foot Ulcers - Pipeline by Human Stem Cells Institute, H1 2017
    Diabetic Foot Ulcers - Pipeline by Izun Pharmaceuticals Corp, H1 2017
    Diabetic Foot Ulcers - Pipeline by Lakewood-Amedex Inc, H1 2017
    Diabetic Foot Ulcers - Pipeline by MediWound Ltd, H1 2017
    Diabetic Foot Ulcers - Pipeline by NovaLead Pharma Pvt Ltd, H1 2017
    Diabetic Foot Ulcers - Pipeline by Oneness Biotech Co Ltd, H1 2017
    Diabetic Foot Ulcers - Pipeline by Osiris Therapeutics Inc, H1 2017
    Diabetic Foot Ulcers - Pipeline by Pherecydes Pharma SA, H1 2017
    Diabetic Foot Ulcers - Pipeline by RMB-Research GmbH, H1 2017
    Diabetic Foot Ulcers - Pipeline by Serodus ASA, H1 2017
    Diabetic Foot Ulcers - Pipeline by Stempeutics Research Pvt Ltd, H1 2017
    Diabetic Foot Ulcers - Pipeline by Stratatech Corp, H1 2017
    Diabetic Foot Ulcers - Pipeline by TechnoPhage SA, H1 2017
    Diabetic Foot Ulcers - Pipeline by Theravasc Inc, H1 2017
    Diabetic Foot Ulcers - Pipeline by Topadur Pharma AG, H1 2017
    Diabetic Foot Ulcers - Pipeline by USV Pvt Ltd, H1 2017
    Diabetic Foot Ulcers - Pipeline by viDA Therapeutics Inc, H1 2017
    Diabetic Foot Ulcers - Pipeline by ViroMed Co Ltd, H1 2017
    Diabetic Foot Ulcers - Dormant Projects, H1 2017
    Diabetic Foot Ulcers - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Diabetic Foot Ulcers - Dormant Projects, H1 2017 (Contd..2) , H1 2017
    Diabetic Foot Ulcers - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Diabetic Foot Ulcers, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Top 10 Routes of Administration, H1 2017
    Number of Products by Stage and Top 10 Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    ANP Technologies Inc
    Anterogen Co Ltd
    Boston Therapeutics Inc
    CardioVascular BioTherapeutics Inc
    Celgene Corp
    Chrysalis BioTherapeutics Inc
    CytoTools AG
    EyeGene Inc
    FirstString Research Inc
    Genentech Inc
    GlaxoSmithKline Plc
    Human Stem Cells Institute
    Izun Pharmaceuticals Corp
    Lakewood-Amedex Inc
    MediWound Ltd
    NovaLead Pharma Pvt Ltd
    Oneness Biotech Co Ltd
    Osiris Therapeutics Inc
    Pherecydes Pharma SA
    RMB-Research GmbH
    Serodus ASA
    Stempeutics Research Pvt Ltd
    Stratatech Corp
    TechnoPhage SA
    Theravasc Inc
    Topadur Pharma AG
    USV Pvt Ltd
    viDA Therapeutics Inc
    ViroMed Co Ltd

    Request for Sample

    Report Url https://www.reportsweb.com//diabetic-foot-ulcers-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//diabetic-foot-ulcers-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//diabetic-foot-ulcers-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments